MAIA Biotechnology, Inc. announced a definitive agreement for a private placement totaling $2.44 million. The proceeds will be used for manufacturing of THIO for clinical trials and working capital.

Company Directors

Accredited Investors

MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is THIO, a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells.

https://maiabiotech.com/

Health Care

Biotechnology

Chicago

MAIA Biotechnology

MAIA Biotechnology, Inc. raised $2.44 million in a private placement led by accredited investors to fund manufacturing for its Phase 2 trial in non-small cell lung cancer.

MAIA Biotechnology, Inc. raised $2.44 million in a private placement led by accredited investors to fund manufacturing for its Phase 2 trial in non-small cell lung cancer.

Investors

Description

Company Information

Related People

Funding Insights

MAIA Biotechnology, Inc. raised $2.44 million in a private placement led by accredited investors to fund manufacturing for its Phase 2 trial in non-small cell lung cancer.

Investors

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Related People

Funding Insights

Company Information